Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

JAMA

Volumn 283, Issue 22, 2000, Pages 2941-2947

  Cannon, Christopher P ^a   Gibson, C Michael ^b   Lambrew, Costas T ^b   Shoultz, David A ^b   Levy, Drew ^b   French, William J ^b   Gore, Joel M ^b   Weaver, W Douglas ^b   Rogers, William J ^b   Tiefenbrunn, Alan J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; ARTICLE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REGRESSION ANALYSIS; REPERFUSION; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0034647275     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.22.2941     Document Type: Article

References (55)

1. Braunwald E. The open-artery theory is alive and well - again. N Engl J Med. 1993;329:1650-1652.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
3. National Heart Attack Alert Program Coordinating Committee-60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med. 1994;23:311-329.
4. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
5. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1994;1:27-34.
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329:673-682.
7. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. W Engl J Med. 1993;328:673-682.
8. Zijlstra F, de Boer MJ, Hoorntje JCA, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. W Engl J Med. 1993;328:680-684.
9. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
10. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy of acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093-2098.
11. Rogers WJ, Dean LS, Moore PB, et al. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 1994; 74:111-118.
12. Every NR, Parsons LS, Hlatky M, et al, for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med. 1996;335:1253-1260.
13. Caputo RP, Ho KK, Stoler RC, et al. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1997;79:1159-1164.
14. Doorey A, Patel S, Reese C, et al. Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty. Am J Cardiol. 1998; 81:1173-1177.
15. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death, 1: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
16. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Circulation. 1999;100: 14-20.
17. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1998;31:967-972.
18. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
19. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley & Sons; 1981.
20. SAS Institute Inc. SAS/STAT Version 6.12. Cary, NC: SAS Institute Inc: 1996.
21. Littell RD, Freund RJ, Spector PD. SAS System for Linear Models. 3rd ed. Cary, NC: SAS Institute Inc; 1991.
22. Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume 1-The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
23. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co; 1986.
24. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127:757-763.
25. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1988;17: 2265-2281.
26. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
27. Jollis JG, Peterson ED, DeLong ER, et al. The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. N Engl J Med. 1994; 331:1625-1629.
28. Anderson JL, Karagounis LA, Muhlestein JB. Explaining discrepant mortality results between primary percutaneous transluminal coronary angioplasty and thrombolysis for acute myocardial infarction. Am J Cardiol. 1996;78:934-939.
29. Hannan EL, Racz M, Ryan TJ, et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA. 1997;277:892-898.
30. McGrath PD, Wennberg DE, Malenka DJ, et al, for the Northern New England Cardiovascular Disease Study Group. Operator volume and outcomes in 12,998 percutaneous coronary interventions. J Am Coll Cardiol. 1998;31:570-576.
31. Ryan TJ, Anderson JL, Antman EM, et al. ACC/ AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996; 28:1328-1428.
32. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Circulation. 1999;100:1016-1030.
33. Gruppo ltaliano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
34. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol. 1996;27: 1646-1655.
35. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol. 1994;49:1-8.
36. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994;24:1602-1610.
37. Goldberg RJ, Mooradd M, Gurwitz JH, et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (the Second National Registry of Myocardial Infarction). Am J Cardiol. 1998;82:259-264.
38. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
39. Cannon CP, Henry TD, Schweiger MJ, et al. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: results of the multicenter TIMI 9 Registry [abstract]. J Am Coll Cardiol. 1995;(special issue):231A-232A.
40. Zahn R, Koch A, Rustige J, et al. Primary angioplasty versus thrombolysis in the treatment of acute myocardial infarction. Am J Cardiol. 1997;79:264-269.
41. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis. 1996;3:117-125.
42. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction. J Am Coll Cardiol. 1998;31:1240-1245.
43. Danchin N, Vaur L, Genes N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world." Circulation. 1999;99:2639-2644.
44. van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999;33:1528-1532.
45. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of TIMI 14 trial Circulation. 1999;99:2720-2732.
46. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction. J Am Coll Cardiol. 1999;34:1954-1962.
47. Ohman EM, Lincoff AM, Bode C, et al. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results of the GUSTO-4 Pilot (SPEED) dose-ranging trial [abstract]. Circulation. 1998;98(suppl 1):1-504.
48. Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary angioplasty procedure volume and major complications. JAMA. 1995;274:1137-1142.
49. Cannon CP. Timely thrombolysis: synergism to open arteries and reduce mortality rates. Am Heart J. 1999;137:1-3.
50. Weaver WD, for the Primary Coronary Angioplasty Trialists Collaboration. Relationship of time to treatment on relative effects of primary coronary angioplasty vs. thromoblytic therapy [abstract]. J Am Coll Cardiol. 2000;35(suppl A):376A.
51. Every NR, Frederick PD, Robinson M, et al. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999;33:1886-1894.
52. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273: 1509-1514.
53. Jollis JG, Peterson ED, Nelson CL, et al. Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. Circulation. 1997;95:2485-2491.
54. Kastrati A, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. J Am Coll Cardiol. 1998;32:970-976.
55. Mercho N, Eldin AM, Shareef B, et al. Angiographic complications of primary angioplasty [abstract]. J Am Coll Cardiol. 1996;27(suppl A):62A.